ZD6474(Vandetanib) + Alimta Combo Study

• Status: Completed
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this trial is to look to see if adding ZD6474 (100 mg or 300mg tablets) to Alimta chemotherapy in patients with non-small cell lung cancer is safe and will help control their symptoms and disease better than the chemotherapy alone.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Genzyme, a Sanofi Company
• Treatments: Pemetrexed

Criteria

Inclusion Criteria:

• Confirmed advanced or metastatic non-small cell lung cancer

• Failure of first-line chemotherapy

• 1 or more measurable lesion by RECIST

Exclusion Criteria:

• Previous chemotherapy or radiotherapy within 4 weeks

• Significant cardiac events, arrythmias or other cardiac conditions

• Unacceptable laboratory measurements